Introduction {#s1}
============

At first glance, mature human red blood cells (RBCs) appear to be simply membranes packed full of hemoglobin, carrying the respiratory gases oxygen and carbon dioxide around the body. They lack all cellular organelles, even the seemingly indispensible nucleus and mitochondria, enabling the maximum volume of the cells to be occupied by hemoglobin. Consequently, RBCs contain extremely high concentrations of hemoglobin (30--35 g/dL) and other impermeant solutes, creating an osmotic imbalance between the intracellular space and the surrounding plasma. Upon closer inspection, the RBC membrane has a greater role to play in RBC function than solely to contain the large amounts of hemoglobin required for oxygen transport. Interactions between RBC membrane proteins and the underlying cytoskeleton maintain the RBC\'s unique biconcave discoid shape that enables the 6 μm cell to deform and pass through 3 μm capillaries and splenic slits. Some of the most abundant RBC membrane proteins are fundamental to the rapid and efficient transport gases, for example Rh-associated glycoprotein (RhAG) and aquaporin 1 (AQP1) transport neutral gases such as carbon dioxide (Endeward et al., [@B41]) and maybe oxygen and/or nitric oxide (Burton and Anstee, [@B26]). The glucose transporter 1 (GLUT1) transports essential metabolites such as glucose (for energy) and dehydroascorbic acid (DHA; for redox homeostasis). The most abundant RBC membrane protein, band 3, exchanges bicarbonate to the plasma in exchange for chloride, a process that is crucial for the efficient transport of carbon dioxide in the blood. This high membrane permeability to anions is in contrast to its very low permeability to cations. In human RBCs it is thought that the cell utilizes its low cation permeability to counteract the osmotic effect of the high solute concentration within the RBCs. Cation gradients across the membrane are actively maintained by pumps keeping intracellular sodium low and intracellular potassium high. This mechanism is tightly regulated to ensure that there is no uncontrolled movement of water into or out of the RBC and is fundamental to cellular volume control (reviewed in Gallagher, [@B49]).

Cation pumps, transporters and channels in the RBC membrane {#s2}
===========================================================

Human RBC membranes contain a number of different cation pumps, transporters and channels (Gallagher, [@B49]). The major protein responsible for maintaining the high potassium, low sodium intracellular state is the Na,K-ATPase, which is an ATP-dependent pump that exchanges 3 sodium ions outwards for 2 potassium ions inwards. Its activity can be specifically inhibited with ouabain. A second major physiologically-active transporter is the NaK2Cl cotransporter (NKCC1), which usually moves 1 Na^+^, 1 K^+^, and 2 Cl^−^ into the cell from the extracellular space, although transport can occur in both directions across the membrane. The NaK2Cl cotransporter is inhibited by the drugs bumetanide and furosemide, cell swelling and urea (Lim et al., [@B81]), and is expressed in numerous cell types. Another ion transporter present in the RBC membrane is the potassium chloride cotransporter (KCC3), which is stimulated by cell swelling and urea. This protein cotransports both potassium and chloride out of the cell, which are accompanied by water and leads to a decrease in cell volume (Lauf and Adragna, [@B79]). The Na-H exchanger (NHE1) is present in RBCs and many other cell types, and is involved in cell volume and pH control. It can be inhibited with the drug amiloride. The cytoplasmic domain of NHE1 interacts with the cytoskeletal protein 4.1, which may play a part in its regulation (Nunomura et al., [@B90]). It is activated by cell shrinking, which is associated with phosphorylation of a number of residues of NHE1 (Rigor et al., [@B100]). The non-selective, voltage-dependent cation (NSVDC) channel (Bennekou and Christopherson, [@B18]) and the K(Na)/H exchanger (Bernhardt and Weiss, [@B19]) are both activated in low ionic strength conditions and may play a role in cation loss in low chloride media, but probably have little role in cation homeostasis at physiological pH and tonicity.

Many of these transporters are regulated by changes in cell volume (swelling and/or shrinkage). The mechanisms underlying this are likely to involve protein-protein interactions, transporter phosphorylation, and cell chloride concentrations (Flatman, [@B45]). Other cation transporting proteins are not thought to play a major role within homeostatic physiological conditions. These include the calcium-activated potassium channel, KCNN4, known as KCa3.1 or the Gardos channel (Hoffman et al., [@B67]). Elevation of intracellular calcium levels activates the Gardos channel to its open conformation, allowing potassium efflux and consequent rapid cellular dehydration. However, this channel usually exists in its dormant closed state, as intracellular calcium is extruded by the Ca^2+^-ATPase. Although the RBC membrane has been very well studied, new insights continue to be made concerning the proteins present and their role in RBC function. There is some evidence from studies in mice that the Kell/XK complex is involved in the regulation of cation homeostasis, as the absence of XK leads to elevated intracellular calcium levels and Gardos channel activation (Rivera et al., [@B101]).

Fairly recently it was discovered that the RBC membrane contains a mechanosensitive cation channel, PIEZO1 (Zarychanski et al., [@B121]). PIEZO1 is encoded by the gene *FAM38A* and can be inhibited by the stretch-activated channel inhibitor, tarantula toxin GsMTx4 (Bae et al., [@B13]). A synthetic small molecule called Yoda1 has been shown to act as a specific PIEZO1 agonist, and may prove to be an important tool for full investigation of the biophysical properties of the channel (Syeda et al., [@B116]). PIEZO1 has been knocked down in zebrafish and mouse, resulting in swelling and lysis of RBCs, suggesting that it is important for cell volume control (Faucherre et al., [@B43]; Cahalan et al., [@B27]), and it has been shown to be important for vascular development (Ranade et al., [@B95]). Evidence from a recent study by Cahalan et al. suggests that PIEZO1-mediated calcium influx activates the Gardos channel and triggers cellular dehydration. This mechanism has been hypothesized to aid the RBC\'s passage through the microvasculature by allowing it to reduce its volume in response to mechanical stimulation or shear stress (Cahalan et al., [@B27]). It will be interesting to discover whether PIEZO1 is directly involved in regulating other RBC membrane cation transporters that are variously stimulated or inhibited by cell swelling, raising the exciting possibility that PIEZO1 is the master regulator of RBC volume control.

Normal membrane ion distribution and fluxes {#s3}
===========================================

In normal human RBCs there is a very low basal permeability to cations. At body temperature, this "leak" is corrected by the Na,K-ATPase, which is present in RBCs at a low copy number, but is sufficient to maintain the sodium/potassium electrochemical gradients. This basal cation permeability can be measured in the presence of the inhibitors ouabain and bumetanide, in order the exclude the activity of the Na,K-ATPase and NaK2Cl transporter, respectively. The temperature-dependence of the potassium leak has been evaluated, and it exhibits an unusual pattern. From 37°C downwards the leak decreases with temperature in a monotonic manner. The minimum of the leak occurs at around 8°C, but below 10°C the leak actually increases with decreasing temperature, resulting in a U-shaped graph (Figure [1](#F1){ref-type="fig"}) (Stewart et al., [@B114]; Coles and Stewart, [@B34]). The explanation for this pattern is not known, and comparisons with other species\' RBCs revealed that human RBCs appear to be unique in this feature (Hall and Willis, [@B64]).

![Temperature dependence of "leak" potassium flux in different leaky membrane variants among the hereditary stomatocytosis conditions. Open symbols denote normal red cells. Closed symbols denote patients, detailed below and in the Table. Potassium influx was measured using ^86^Rb as a tracer. The medium contained (mM): Na^+^, 145: K^+^, 5; Cl^−^, 150, MOPS, 15 (pH 7.4 at 20°C); glucose, 5; ouabain, 0.1; bumetanide, 0.1. Reproduced with permission from Stewart ([@B110]).](fphys-09-00367-g0001){#F1}

Comparison of human with other species\' RBCs {#s4}
=============================================

Intriguingly, this use of cation gradients for regulation of cell volume in human RBCs does not appear to be a common feature of other mammals\' RBCs. Dogs, sheep and cows are all species in which individuals\' RBC phenotype may be categorized as either "high K" or "low K" (Chan et al., [@B31]; Gibson, [@B51]). In dogs the "low K" phenotype is most common, and this is inherited in an autosomal dominant manner. Despite the fact that the potassium levels of "high K" dog RBCs are most similar to the normal state of human RBCs, they exhibit signs of overhydration, including increased osmotic fragility, increased cell size, reduced cell hemoglobin concentration and reduced RBC lifespan. Studies of dog RBCs suggest that they employ a different mechanism for regulating their volume, predominantly involving the Na/H exchanger and KCl cotransporter (Parker et al., [@B93]). "High K" dog RBCs have higher levels of the Na,K-ATPase, which is thought to be responsible for the unusual cation gradients, and in this species its expression appears to be detrimental. It has been shown that both "low K" and "high K" dog reticulocytes express Na,K-ATPase and produce exosomes containing the protein, but "high K" erythroid progenitor cells express higher levels (Komatsu et al., [@B75]). The genetic basis of the "high K" vs. "low K" phenotype has not yet been established, but may provide a clue concerning the regulation of Na,K-ATPase expression.

Studies using duck RBCs have shown that their volume regulation involves coordinated transport by NaK2Cl cotransporter and KCl cotransporter proteins (Lytle and McManus, [@B83]), highlighting that there are many ways to control RBC volume, utilizing different transporters to achieve this goal.

Mice are often used as a model for the human system, however evaluation of a number of different mouse strains has revealed that their cation content and transporter activity are different depending on the strain and gender of the mouse (Rivera et al., [@B102]). These observations may be useful in the investigation of genetic determinants of ion transport.

Conditions involving disturbances in ion fluxes {#s5}
===============================================

It has become apparent that a number of factors can affect the cation permeability of the human RBC membrane. These include the use of certain drugs and oxidation of membranes. A recent study using aquaporin-9 knock-out mouse RBCs showed that oxidative modification of aquaporin-9 increases the cation permeability of the RBC membrane (Kucherenko et al., [@B76]). The presence of certain disease states results in aberrant membrane ion flux. Increased cation permeability has been recorded in thalassemia and chronic dyserythropoietic anemia (CDA), where the bone marrow is under continual stress (Wiley, [@B120]). Cation fluxes are also disturbed in a group of inherited disorders collectively known as the hereditary stomatocytoses. Although a common theme running throughout these disorders is that cation permeability of the RBC membrane is perturbed, these disorders show wide heterogeneity in the severity and characteristics of their cation leaks and also accompanying symptoms (Table [1](#T1){ref-type="table"}). These are an extensively-studied group whose molecular bases remained unknown for a long time, but for the vast majority these have now been elucidated and form the basis of this review.

###### 

Hereditary stomatocytosis pedigrees and other cation-leaky membrane disorders.

  **Clinical/hematology**     **Genetics/biochemistry**                                                                                                                                                              
  --------------------------- --------------------------- ----------------------------------- ----------- ---------- ------- --------------- ------------------------------ ---------- ----------------------------- -------------------------------------------------
  OHSt 1                      Stockport                   Stomatocytes                        \+          Normal     × 40    Monotonic       Lock et al., [@B82]            *RHAG*     Phe65Ser                      Bruce et al., [@B23]
  OHSt 1                      Albuquerque                 Stomatocytes                        No splen.   Normal     × 40    Monotonic       Fricke et al., [@B48]          *RHAG*     Phe65Ser                      Bruce et al., [@B23]
  OHSt 1                      Brighton                    Stomatocytes (30--40%)              \+                     × 40    Monotonic       Meadow, [@B85]                 *RHAG*     Phe65Ser                      Bruce et al., [@B23]
  OHSt 1                      Toulouse                    Stomatocytes                        No splen.              × 40    Monotonic       Fricke et al., [@B48]          *RHAG*     Phe65Ser                      Bruce et al., [@B23]
  OHSt 1                      Grenoble                    Stomatocytes (15--20%)              No splen.              × 40    Monotonic       Morlé et al., [@B89]           *RHAG*     Phe65Ser                      Bruce et al., [@B23]
  OHSt 1                      Nancy                       Stomatocytes (10--20%)              Unknown                × 40    Monotonic       Bruce et al., [@B23]           *RHAG*     Phe65Ser                      Bruce et al., [@B23]
  OHSt 2                      Harrow                      Stomatocytes                        No splen.              × 40    Monotonic       Fricke et al., [@B48]          *RHAG*     Ile61Arg                      Bruce et al., [@B23]
  sdCHC + neuro.              Montpellier                 Stomatocytes                        No splen.              × 10    U-shaped        Fricke et al., [@B48]          *SLC2A1*   Gly286Asp                     Flatt et al., [@B46]
  sdCHC + neuro.              San Francisco               Unknown                             No splen.              × 10    U-shaped        Fricke et al., [@B48]          *SLC2A1*   ΔIle435/436                   Flatt et al., [@B46]
  sdCHC + neuro.              n/a                         Echinocytes, stomatocytes           No splen.                      n.t.            Bawazir et al., [@B16]         *SLC2A1*   ΔIle435/436                   Bawazir et al., [@B16]
  PED + cation leak           n/a                         Echinocytes (14--40%)               No splen.                      n.t.            Weber et al., [@B119]          *SLC2A1*   Δ282--285                     Weber et al., [@B119]
  CHC                         Hemel                       Stomatocytes (30%)                  −           \+ ether   × 4     U-shaped        Coles et al., [@B32]           *SLC4A1*   Ser731Pro                     Bruce et al., [@B25]
  CHC                         Watford                     Stomatocytes                        −           \+ ether   × 4     U-shaped        Coles et al., [@B32]           *SLC4A1*   Ser731Pro                     Bruce et al., [@B25]
  CHC                         Bushey                      Stomatocytes                        −           \+ ether   × 4     U-shaped        Haines et al., [@B63]          *SLC4A1*   Ser731Pro                     Bruce et al., [@B25]
  CHC                         Milton Keynes                                                   No splen.              × 4     U-shaped        Stewart, [@B110]               *SLC4A1*   Ser731Pro                     Bruce et al., [@B25]
  CHC                         Hurstpierpoint              Stomatocytes (15--20%)              −           Normal     × 4     U-shaped        Haines et al., [@B63]          *SLC4A1*   His734Arg                     Bruce et al., [@B25]
  CHC                         Zurich                                                          No splen.              × 4     U-shaped        Stewart, [@B110]               *SLC4A1*   His734Arg                     Bruce et al., [@B25]
  CHC                         Islington                                                                                      n.t.            Stewart, [@B110]               n.t.                                     
  CHC                         n/a                         Stomatocytes, spherocytes                                  × 3     U-shaped        Guizouarn et al., [@B59]       *SLC4A1*   Ser762Arg                     Guizouarn et al., [@B59]
  SAO                         n/a                         Stomatocytic ovalocytes                                    × 2     U-shaped        Guizouarn et al., [@B59]       *SLC4A1*   Δ400--408                     Tanner et al., [@B118]
  HS-LTL                      Cricklewood                 Spherocytes                         No splen.                                      Bruce et al., [@B25]           *SLC4A1*   Arg760Gln                     Bruce et al., [@B25]
  HS-LTL                      Dagenham                    Spherocytes                         No splen.                                      Bruce et al., [@B25]           *SLC4A1*   Arg760Gln                     Bruce et al., [@B25]
  HS-LTL                      Eastbourne                  Spherocytes                         \+                                             Gore et al., [@B55]            *SLC4A1*   Asp705Tyr                     Bruce et al., [@B25]
  HSt Blackburn               Blackburn                   Stomatocytes                        \+          Normal     × 4     Shallow slope   Coles et al., [@B33]           *SLC4A1*   Leu687Pro                     Bruce et al., [@B25]
  HSt Blackburn               Darlington                  Stomatocytes (5--10%)               \+                     × 3     Shallow slope   Gore et al., [@B57]            *SLC4A1*   Leu687Pro                     Bruce et al., [@B25]
  HSt Blackburn               Bergen                                                          \+                     × 4     Shallow slope   Stewart, [@B110]               n.t.                                     
  HSt Blackburn               St. Etienne                                                     \+                     × 4     Shallow slope   Stewart, [@B110]               n.t.                                     
  Band 3 New Haven            Patient 1                   Rare stomatocytes                                                                  Stewart et al., [@B109]        *SLC4A1*   Glu758Lys                     Stewart et al., [@B109]
  Band 3 New Haven            Patient 2                   Mild anisocytosis                                                                  Stewart et al., [@B109]        *SLC4A1*   Glu758Lys                     Stewart et al., [@B109]
  HSt variant                 Stanford                    Normal, rare stomatocytes           Unknown                × 6                     Stewart et al., [@B108]        *SLC4A1*   Arg730Cys                     Stewart et al., [@B108]
  Band 3 Ceinge + dyseryth.   Ceinge                      Anisopoikilocytosis                                                                Iolascon et al., [@B70]        *SLC4A1*   Gly796Arg                     Iolascon et al., [@B70]
  FP                          Cardiff                     Normal                              No splen.   \+ ether   × 1     U-shaped        Gore et al., [@B56]            *ABCB6*    Arg723Gln                     Bawazir et al., [@B15]
  FP                          Cumbria                     Normal                                                     × 1     U-shaped        Bawazir et al., [@B15]         *ABCB6*    Arg723Gln                     Bawazir et al., [@B15]
  FP                          Harrow                      Normal                                                     × 1     U-shaped        Bawazir et al., [@B15]         *ABCB6*    Arg723Gln                     Bawazir et al., [@B15]
  FP                          Cardiff-2                                                                                                      Andolfo et al., [@B8]          *ABCB6*    Arg723Gln /Arg276Trp          Andolfo et al., [@B8]
  FP                          Bolivian                                                                                                       Andolfo et al., [@B8]          *ABCB6*    Val454Ala                     Andolfo et al., [@B8]
  FP                          Lille                                                                                                          Dagher et al., [@B36]          *ABCB6*    Arg375Gln                     Andolfo et al., [@B5]
  FP                          Chiswick                    Normal                              No splen.   Normal     × 1.5   Shoulder        Haines et al., [@B62]          *ABCB6*    Arg375Gln                     Bawazir et al., [@B15]
  FP                          White City                                                                                                     Bawazir et al., [@B15]         *ABCB6*    Arg375Gln                     Bawazir et al., [@B15]
  FP                          Falkirk                                                         No splen.   Normal     × 1.5   Shoulder        Haines et al., [@B63]          *ABCB6*    Arg375Trp                     Andolfo et al., [@B5]
  FP                          Bow                         Normal, rare stomatocytes           No splen.   Normal     × 1.5   Shoulder        Gore et al., [@B57]            *ABCB6*    Arg375Trp                     Andolfo et al., [@B5]
  FP/DHSt                     Irish                                                           \+                                             Stewart et al., [@B111]        *ABCB6*    Arg276Trp                     Andolfo et al., [@B8]
  DHSt M\'brough              Middlesbrough               Target cells, rare stomatocytes                            × 4     Flat to 30      Gore et al., [@B57]                                                     
  DHSt M\'brough              Birmingham                  Target cells                                               × 2     Flat to 30      Gore et al., [@B57]                                                     
  HSt variant                 Woking                      Stomatocytes (5--10%)               No splen.              × 4     Parallel        Jarvis et al., [@B72]                                                   
  DHSt + ascites              Bury St. Edmunds                                                                       × 2     Sigmoidal       Stewart, [@B110]                                                        
  DHSt + ascites              Sunderland                  Anisocytosis, target cells          No splen.              × 2     Sigmoidal       Basu et al., [@B14]                                                     
  DHSt                        Kyoto                       Rare stomatocytes                               \+ PC                              Imashuku et al., [@B69]        *FAM38A*   Glu2496GluLeuGlu              Imashuku et al., [@B69]
  DHSt                        Case 1                                                                                                         Albuisson et al., [@B1]        *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt                        Case 2                                                                                                         Albuisson et al., [@B1]        *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt                        Case 3                                                                                                         Albuisson et al., [@B1]        *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt                        Case 5                                                                                                         Albuisson et al., [@B1]        *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt                        Case 6                                                                                                         Albuisson et al., [@B1]        *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt                        Case 7                                                                                                         Albuisson et al., [@B1]        *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt + ascites              Vesoul                                                          \+                     × 2                     Grootenboer et al., [@B58]     *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt + FP                   Family 3                                                        \+          +PC                                Carli et al., [@B29]           *FAM38A*   Glu2496GluLeuGlu              Albuisson et al., [@B1]
  DHSt + ascites              Patient 6                                                       No splen                                       Glogowska et al., [@B54]       *FAM38A*   Glu2496GluLeuGlu              Glogowska et al., [@B54]
  DHSt                        Patient 7                                                       No splen                                       Glogowska et al., [@B54]       *FAM38A*   Glu2496GluLeuGlu              Glogowska et al., [@B54]
  DHSt + ascites              Patient 8                                                       \+                                             Glogowska et al., [@B54]       *FAM38A*   Glu2496GluLeuGlu              Glogowska et al., [@B54]
  DHSt                        Patient 9                                                       \+                                             Glogowska et al., [@B54]       *FAM38A*   Glu2496GluLeuGlu              Glogowska et al., [@B54]
  DHSt                        Family A (UK)               Schistocytes, rare stomatocytes                                                    Andolfo et al., [@B6]          *FAM38A*   Glu2496GluLeuGlu              Andolfo et al., [@B6]
  DHSt                        Family B (Italy)            Schistocytes, rare stomatocytes                                                    Andolfo et al., [@B6]          *FAM38A*   Glu2496GluLeuGlu/Arg1864His   Andolfo et al., [@B6]
  DHSt + FP                   Arras                                                           \+                                             Grootenboer et al., [@B58]     *FAM38A*   Arg2488Gln /Gly718Ser         Andolfo et al., [@B4]
  DHSt                        Boston                      Target cells                                                                       Platt et al., [@B94]           *FAM38A*   Arg2488Gln                    Archer et al., [@B11]
  DHSt + ascites              Patient 3                                                       No splen                                       Glogowska et al., [@B54]       *FAM38A*   Arg2488Gln                    Glogowska et al., [@B54]
  DHSt                        Canada                      Target cells, schistocytes                                                         Houston et al., [@B68]         *FAM38A*   Arg2456His                    Zarychanski et al., [@B121] Bae et al., [@B12]
  DHSt                        San Francisco                                                                                                  Grootenboer et al., [@B58]     *FAM38A*   Arg2456His                    Andolfo et al., [@B4]; Bae et al., [@B12]
  DHSt                        Rosedale                    Macrocytes, stomatocytes                                                           Shmukler et al., [@B107]       *FAM38A*   Arg2456His                    Shmukler et al., [@B107]
  DHSt                        Denmark                     Normal                                                                             Sandberg et al., [@B106]       *FAM38A*   Arg2456His                    Sandberg et al., [@B106]
  DHSt + ascites              Nantes family 1             Target cells, rare stomatocytes                                                    Beneteau et al., [@B17]        *FAM38A*   Arg2456His                    Beneteau et al., [@B17]
  DHSt + ascites              Nantes family 2             Target cells, rare stomatocytes                                                    Beneteau et al., [@B17]        *FAM38A*   Arg2456His                    Beneteau et al., [@B17]
  DHSt                        Burnley                                                         No splen.   \+ PC      × 2     Parallel        Stewart, [@B110]               *FAM38A*   Arg2456His                    Unpublished, LJ Bruce 2018
  DHSt                        Nuneaton                                                        \+          \+ PC      × 2     Parallel        Stewart, [@B110]               *FAM38A*   Arg2456His                    Unpublished, LJ Bruce 2018
  DHSt                        Patient 4                                                       No splen                                       Glogowska et al., [@B54]       *FAM38A*   Arg2302His                    Glogowska et al., [@B54]
  DHSt                        New York                    Stomatocytes (up to 35% hom)                    Normal                             Miller et al., [@B87]          *FAM38A*   Met2225Arg                    Zarychanski et al., [@B121]; Bae et al., [@B12]
  DHSt                        Dax                                                                                                            Grootenboer et al., [@B58]     *FAM38A*   2166-2169delLys               Andolfo et al., [@B4]
  DHSt + FP                   Edinburgh                   Target cells                        No splen.   Normal     × 1.1   Shallow slope   Stewart and Ellory, [@B113]    *FAM38A*   Thr2127Met                    Andolfo et al., [@B4]
  DHSt                        Case 8                                                                                                         Albuisson et al., [@B1]        *FAM38A*   Thr2127Met                    Albuisson et al., [@B1]
  DHSt                        Patient 2                                                       No splen                                       Glogowska et al., [@B54]       *FAM38A*   Arg2088Gly                    Glogowska et al., [@B54]
  DHSt + FP                   Vanves                      Rare stomatocytes                                          × 1.5                   Grootenboer et al., [@B58]     *FAM38A*   Ala2020Thr                    Albuisson et al., [@B1]
  DHSt                        Essex                                                                                                          Carella et al., [@B28]         *FAM38A*   Ala2020Val/Ser1117Leu         Andolfo et al., [@B4]
  DHSt                                                    Stomatocytes                                                                       Paessler and Hartung, [@B91]   *FAM38A*   c.6239_6256dup18              Paessler and Hartung, [@B91]
  DHSt                        Troyes                                                          \+                                             Grootenboer et al., [@B58]     *FAM38A*   Ala2003Asp                    Andolfo et al., [@B4]
  DHSt                        Patient 1                                                       No splen                                       Glogowska et al., [@B54]       *FAM38A*   Arg1943Gln                    Glogowska et al., [@B54]
  DHSt                        Case 4                      Rare stomatocytes                                                                  Syfuss et al., [@B117]         *FAM38A*   Arg1358Pro                    Albuisson et al., [@B1]
  DHSt + FP + ascites         Bicetre                                                                                                        Grootenboer et al., [@B58]     *FAM38A*   Arg808Gln/Gly782Ser           Andolfo et al., [@B4]
  DHSt                        Italy                       Stomatocytes                        \+                                             Fermo et al., [@B44]           *KCNN4*    Arg352His                     Rapetti-Mauss et al., [@B96]
  DHSt                        France                      Anisocytosis                                                                       Rapetti-Mauss et al., [@B96]   *KCNN4*    Arg352His                     Rapetti-Mauss et al., [@B96]
  DHSt                        Poland                      Anisocytosis                                                                       Rapetti-Mauss et al., [@B96]   *KCNN4*    Arg352His                     Andolfo et al., [@B9]
  DHSt                        Naples                      Anisopoikilocytosis, stomatocytes                                                  Andolfo et al., [@B9]          *KCNN4*    Arg352His                     Andolfo et al., [@B9]; Glogowska et al., [@B53]
  DHSt                        Worcester                                                                              × 3                     Grootenboer et al., [@B58]     *KCNN4*    Val282Met                     Glogowska et al., [@B53]
  DHSt                        French/Irish                Target cells, acanthocytes                                                         Glader et al., [@B52]          *KCNN4*    Val282Glu                     Fermo et al., [@B44]

Hereditary stomatocytoses {#s6}
=========================

Despite the lack of information concerning the molecular cause(s) of the hereditary stomatocytoses (HSt), great efforts were made to thoroughly characterize the cation leaks exhibited by the known pedigrees. These analyses further underlined the wide heterogeneity of the disorders. Prof. G. Stewart classified the pedigrees into distinct types according to various factors, including the severity and temperature-dependence of the cation leak (Stewart, [@B110]) (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). As recent breakthroughs have provided more information regarding the molecular basis of HSt, it has become clear that these phenotypes elegantly segregate with distinct genetic backgrounds.

HSt mutations in large multi-spanning membrane proteins {#s7}
=======================================================

Band 3 mutations
----------------

### Cryohydrocytosis

Cryohydrocytosis (CHC) is so named because of the temperature-dependence of the cation leak. Although CHC cells have increased basal cation permeability at physiological temperatures, this leak becomes much more pronounced when the cells are cooled to below 10°C (Figure [1B](#F1){ref-type="fig"}). Cryohydrocytosis was the first of the hereditary stomatocytoses in which the genetic basis was established. Heterozygous single amino acid substitutions in the band 3 protein (SLC4A1) were identified in 11 stomatocytosis pedigrees (Bruce et al., [@B25]). Band 3 is responsible for anion exchange across the plasma membrane, however in each of these pedigrees the mutant band 3 proteins were unable to transport anions even when expressed in the RBC membrane. Instead, expression of the mutant protein resulted in the temperature-sensitive increase in the permeability of the RBC membrane to cations.

All of the band 3 HSt mutations identified so far occur within the transmembrane domain between spans 8 and 12, the region that forms the transport channel of band 3 (Figure [2](#F2){ref-type="fig"}; Arakawa et al., [@B10]; Reithmeier et al., [@B99]). The mutant proteins were shown to be expressed in the CHC patients\' RBCs and they induced a cation leak when expressed heterologously in *Xenopus levis* oocytes. The ouabain and bumetanide insensitive cation leak could be inhibited with a range of specific band 3 inhibitors, supporting the hypothesis that the cation leak is mediated directly through the transport channel of band 3 (Bruce et al., [@B25]). There is variability in the phenotype depending on the mutation. Two mutations were initially identified as corresponding to the classic CHC phenotype: Ser731Pro and His734Gln (Bruce et al., [@B25]), both occurring very close to each other in transmembrane domain 10 of band 3 (Arakawa et al., [@B10]). His734 is an essential residue for anion transport and Ser731 lie close to the transport site (Arakawa et al., [@B10]). Further CHC mutations have since been reported in the same region of the protein, including Ser762Arg (Guizouarn et al., [@B59]) in span 11 of band 3. This residue interacts with His734 in TM10 (Arakawa et al., [@B10]; Reithmeier et al., [@B99]).

![Diagram of the membrane domain of band 3 showing the membrane spans and HSt mutations. The length of the membrane spans mimics that determined from the crystal structure by Arakawa et al. ([@B10]). In the final structure the half transmembrane span 3 and half transmembrane span 10 form a full transmembrane domain (TM) jointly (Arakawa et al., [@B10]). The nine amino acid residues deleted in SAO band 3 are shown in blue. The amino acid residues associated with HSt are shown in orange. The Asp705Tyr (TM9), Arg730Cys (TM10), Ser731Pro (TM10), His734Arg (TM10) Glu758Lys (TM11), Arg760Gln (TM11), and Ser762Arg (TM11) mutations all occur close to the anion binding site of band 3. The Gly796Arg mutation is in TM12 and may affect helix-helix packing. The Leu687Pro mutation is near the C-terminus of TM8 which is at the interface of the core and gate domains. Movement between these two domains is required for anion transport and substitution of Leu687 with a proline residue may restrict this movement (Arakawa et al., [@B10]).](fphys-09-00367-g0002){#F2}

One subtype within the cryohydrocytosis group referred to as HS-LTL (hereditary spherocytosis with low temperature leak) results from the mutation Asp705Tyr or Arg760Gln (Bruce et al., [@B25]) and shows some overlap with the hereditary spherocytosis (HS) group of disorders. In those disorders the vertical link between the RBC cytoskeleton and the membrane is disrupted because of defects in the structurally important proteins band 3, protein 4.2 or ankyrin. In typical HS (without a cation leak) the mutant band 3 may be too misfolded to reach the membrane at all, or the mutant mRNA is unstable and is degraded. The remaining wild type allele produces functional band 3, but not in sufficient quantity to fully compensate for the lost structural interactions. The weakening of the link between the membrane and the underlying cytoskeleton results in the loss of membrane, producing small and dense spherocytic cells. In HS-LTL there is a deficiency in the vertical interactions between the cytoskeleton and band 3 in the membrane, resulting in the same spherocytic morphology, but the difference is that some of the mutant band 3 is successfully trafficked to the membrane, despite being misfolded. Once expressed at the plasma membrane the mutant protein causes a RBC cation leak.

### Southeast asian ovalocytosis

Southeast Asian Ovalocytosis (SAO) cells are morphologically abnormal, showing large oval cells often with double slits on blood films. The mutation in SAO band 3 is a 9 amino acid deletion at residues 400--408 (Tanner et al., [@B118]) (Figure [2](#F2){ref-type="fig"}). This region is situated close to the boundary of the large cytoplasmic N-terminal domain and the transmembrane domain and it is known to affect the normal folding of band 3 (Kuma et al., [@B77]). Like CHC band 3, the SAO band 3 is expressed in the RBC membrane but is misfolded and cannot transport anions. Early *in vitro* studies of SAO RBCs indicated that these cells were resistant to invasion by the malaria parasite, *Plasmodium falciparum* (Hadley et al., [@B61]). However, further experimental study showed that a significant part of this effect is caused by depletion in the cellular levels of ATP upon storage of these cells (Dluzewski et al., [@B39]). This is an effect resulting from a cold-induced cation leak (Bruce et al., [@B24]), which is almost indistinguishable from that observed in CHC (Guizouarn et al., [@B59]). However, the SAO mutation has been shown to confer protection from cerebral malaria---a serious complication that can arise from *P. falciparum* infection (Allen et al., [@B2]), and this could explain the prevalence of SAO in low-lying parts of Papua New Guinea and South East Asia.

### Other HSt caused by band 3 mutations

HSt Blackburn is another distinct type of cation leak with a characteristic temperature-dependence. This has previously been described as the "shallow slope" type, where cells exhibit a cation leak 4--5 times greater than normal cells at 37°C, but as the temperature lowers only a small decrease in this leak is observed (Figure [1C](#F1){ref-type="fig"}; Coles and Stewart, [@B34]). This phenotype is associated with a band 3 point mutation, Leu687Pro, which prevents normal anion exchange function and produces a cation leak when expressed in *X. levis* oocytes (Bruce et al., [@B25]). Leu687 is at the C-terminus of TM8, which packs against TM3 and TM10 (Figure [2](#F2){ref-type="fig"}). TM8 is at the interface of the core and gate domains of band 3 (Arakawa et al., [@B10]) and therefore key to the normal functioning of band 3.

Band 3 New Haven (Glu758Lys) has been reported in 2 patients (Stewart et al., [@B109]). Expressing this mutant band 3 in oocytes produced anion exchange activity only when GPA was co-expressed, but the cation leak associated with its expression was GPA-independent. These characteristics are in contrast to other HSt band 3 mutations, where anion exchange was completely abolished. The same group also reported a further band 3 mutation in HSt (Arg730Cys) (Stewart et al., [@B108]). The temperature-dependence of the leaks caused by these two mutations were not characterized.

Band 3 Ceinge (Gly796Arg) is an interesting HSt variant, as this pedigree exhibited signs of dyserythropoiesis and no mutations were found in *CDAN1*, the gene associated with chronic dyserythropoietic anemia (CDA) type 1. Analysis of the membranes also revealed increased tyrosine phosphorylation of band 3 and other membrane proteins (Iolascon et al., [@B70]).

RhAG mutations
--------------

### Overhydrated hereditary stomatocytosis

The most severe cation leak in the hereditary stomatocytoses can be found in a condition known as overhydrated hereditary stomatocytosis (OHSt). At 37°C the cation leak can be as high as 40 times greater than normal; the temperature dependence profile shows a simple pattern of increasing leak with increasing temperature (Figure [1A](#F1){ref-type="fig"}; Coles and Stewart, [@B34]). Heterozygous mutations in *RHAG* are associated with this disorder---Phe65Ser and Ile61Arg---and again these fall within a transmembrane span (Bruce et al., [@B23]). This gene encodes the Rh-associated glycoprotein (RhAG), which is distantly related to ammonia transporters in bacteria and yeast (Marini et al., [@B84]). Molecular modeling of the mutant RhAG suggests that the Phe65Ser mutation causes a significant widening of the central transport channel, converting it into a non-selective cation pore (Bruce et al., [@B23]). Ile61Arg is also predicted to widen the central channel, but not to the same extent. It was noted that larger structural changes may occur, which would allow passage of cations. In addition, there is experimental evidence that the OHSt mutation Phe65Ser prevents the transport of ammonia, which is thought to be the normal substrate of RhAG (Genetet et al., [@B50]).

A metabolomics study of four individuals with OHSt has provided an insight into the downstream effects of this RhAG mutation (Darghouth et al., [@B38]). The authors found that the glycolytic pathway is overactive in OHSt RBCs, with a build-up of glycolysis end products. This is consistent with an increased energy demand in OHSt cells, possibly resulting from elevated activity of the Na,K-ATPase attempting to maintain normal cation gradients. An unexpected finding in the metabolomics study was an alteration in levels of certain members of oxidation pathways, raising the possibility that OHSt RBCs may also suffer from previously unrecognized oxidative stress (Darghouth et al., [@B38]).

### Stomatin

Stomatin first attracted attention when it was observed to be deficient in the membranes of overhydrated stomatocytosis RBCs, and was named after the disease (Lande et al., [@B78]; Stewart et al., [@B115]). Initially it appeared that the disease must be caused by the absence of this protein, however further investigation revealed that stomatin deficiency was a secondary effect of the disorder (Fricke et al., [@B47]). It is now known that the primary defect is mutation in RhAG. Since then, a second type of hereditary stomatocytosis has been observed to be deficient in stomatin (sdCHC, see below).

Interestingly, the levels of stomatin are also significantly higher in dog RBCs of the "high K" phenotype and its expression can be used as a marker for the phenotype (Komatsu et al., [@B75]).

The precise role of stomatin in the RBC has become a long-running debate, although potential roles have been plentiful. Studies using a wide variety of organisms have provided evidence that stomatin is involved in cholesterol binding, actin binding, vesiculation and regulation of ion channels. In species unable to synthesize vitamin C *de novo*, stomatin converts GLUT1 into a transporter of oxidized vitamin C (dehydroascorbic acid; DHA), which is crucial for its recycling (Montel-Hagen et al., [@B88]).

Cross-linking experiments also implicate stomatin in RBC protein complexes with GLUT1, band 3, aquaporin-1 and other membrane transporters and proteins (Rungaldier et al., [@B104]). Stomatin is able to form higher order homo-oligomeric complexes in the RBC membrane and probably acts as a scaffolding protein (Salzer and Prohaska, [@B105]).

### Rh~null~

The molecular basis of Rh~null~ (regulator type) is mutation in both alleles of *RHAG*, resulting in the absence of RhAG and its closely associated partner proteins from the RBC membrane. Rh~null~ (amorph type) occurs when an RhD-negative individual also has mutations in both alleles of *RHCE*, in which case RhAG is only weakly expressed (Cartron, [@B30]). This deficiency of the Rh protein complex is associated with a number of as yet unexplained features including altered membrane phospholipid asymmetry, occasional stomato-spherocytic morphology and a mild cation leak (reviewed by Cartron, [@B30]). Patients usually experience chronic mild to moderate hemolytic anemia.

Analysis of morphologically normal Rh~null~ RBCs revealed normal cation and water content but an increase in the basal membrane permeability to potassium and the ouabain and bumetanide sensitive potassium permeability. Consistent with the observed increase in active potassium transport, the number of Na,K-ATPase molecules in the Rh~null~ RBCs was greater than normal by 35--45% (Lauf and Joiner, [@B80]). The temperature-dependence of the leak has not been established.

There is evidence that protein-lipid interactions are altered in Rh~null~ RBCs (Dorn-Zachertz and Zimmer, [@B40]). Band 3 has been shown to interact strongly with RhAG, so its absence is likely to disrupt the correct formation of the band 3 macrocomplex (Bruce et al., [@B22]). More work is needed to elucidate the mechanism behind the increased cation permeability previously observed in 2 cases of Rh~null~. However, the lack of availability of this extremely rare blood type is restrictive for comprehensive studies.

GLUT1 mutations
---------------

Stomatin-deficient cryohydrocytosis (sdCHC) is a very rare type of HSt, and has only been reported in 3 patients to date (Bawazir et al., [@B16]). Alongside a RBC cation leak that is 10 times greater than normal at 37°C (Figure [1B](#F1){ref-type="fig"}) these patients also suffer from numerous non-hematological symptoms that do not occur in any of the other types of hereditary stomatocytosis. These include cataracts and a debilitating neurological phenotype comprising seizures and severe learning difficulties. The gene responsible has been identified as *SLC2A1*, encoding glucose transporter isoform 1 (GLUT1). GLUT1 is the major glucose transporter expressed in RBCs and at the blood-brain barrier. Two distinct mutations in *SLC2A1* have been found in sdCHC patients (Flatt et al., [@B46]). In the Montpellier pedigree a single amino acid substitution mutation was found (Gly286Asp), whilst the San Francisco pedigree exhibited a single amino acid deletion (Ile435 or Ile436). In an analogous situation to the RhAG mutants in OHSt and some of the band 3 mutants in CHC, the GLUT1 mutants lost their ability to transport their usual substrate, and instead induced a cation leak when expressed heterologously in *X. levis* oocytes.

GLUT1 mutations have also been shown to result in a RBC cation leak in one pedigree suffering from another condition called paroxysmal exertion-induced dyskinesia (PED) (Weber et al., [@B119]). In PED involuntary movements are brought on by exercise, and it is not normally associated with a RBC cation leak. In this case the mutation in GLUT1 was identified as a deletion of residues 282--285, which is immediately adjacent to the substitution mutation identified in sdCHC. This mutation occurs within transmembrane span 7, which has been shown to be crucial for transport function. Modeling of the mutant protein suggested that the central pore is widened. Unlike in sdCHC, these RBCs exhibited spiky protrusions (echinocytosis), which are often associated with cellular dehydration. The permeability of the RBCs to sodium, potassium and calcium was increased, raising the possibility that calcium influx might be sufficient to activate the Gardos channel and trigger rapid potassium efflux and cellular dehydration, explaining the echinocytosis (Weber et al., [@B119]).

Mutations in GLUT1 are also associated with GLUT1-deficiency syndrome (GLUT1-DS). This disorder shows some heterogeneity in its severity and symptoms (Brockmann, [@B21]). However, there does appear to be a correlation between the effect on glucose transport and clinical severity (Rotstein et al., [@B103]). Inactivating mutations in one allele result in \~50% reduction in glucose transport, and these are the most common form of GLUT1-DS. Other missense mutations appear to impact glucose transport in a minor way, resulting in an asymptomatic or mild phenotype. Compound heterozygosity or homozygosity for a "mild" mutation could therefore result in a severe phenotype where glucose transport is reduced by more than 50%. A reduction of 75% or more is likely to be embryonic lethal (Rotstein et al., [@B103]).

ABCB6 mutations
---------------

The condition, familial pseudohyperkalemia (FP), is a very mild form of HSt that can often be asymptomatic. The condition was first reported in 1979 (Stewart et al., [@B112]), although FP in this cohort was later shown to map to the 16q23-ter locus (Iolascon et al., [@B71]) and result from a mutation in PIEZO1 (Andolfo et al., [@B4]). A detailed analysis of the temperature sensitivity of the potassium flux was described in 1985 (Meenaghan et al., [@B86]). At the physiological temperature of 37°C the cation leak is practically indistinguishable from normal, being only 1.1--1.5 times the normal rate (Stewart, [@B110]). The close to normal cation permeability at 37°C means that samples of FP blood when tested immediately after venesection show normal hematological parameters. However, after cooling to room temperature and/or refrigeration the cation leak is "activated" and a rise in plasma potassium occurs after a period of cool or room temperature storage. Although all FP cases share this feature, the heterogeneity in the temperature-dependence of their cation leaks means that the degree of potassium efflux varies between the different subtypes at different temperatures.

The temperature dependences of the cation leaks in the FP pedigrees are shown in Figure [1](#F1){ref-type="fig"}, and include U-shaped (Figure [1B](#F1){ref-type="fig"}), shallow slope (Figure [1C](#F1){ref-type="fig"}) and shoulder types (Figure [1D](#F1){ref-type="fig"}). All show a cation leak very similar to the control at 37°C which increases as the temperature decreases. The molecular bases of a number of FP pedigrees have been determined recently, with mutations in the ATP-binding cassette family member B6 (ABCB6) identified as responsible (Andolfo et al., [@B5], [@B8]; Bawazir et al., [@B15]). The ABCB6 protein is a porphyrin transporter that is considered to be a mitochondrial protein, but has also been detected in lysosomes and the RBC plasma membrane (Kiss et al., [@B74]). Indeed, it has also been discovered that ABCB6 carries the antigens of the Langereis blood group system (Helias et al., [@B66]).

Two of the *ABCB6* mutations affect the same residue in the protein (R375Q and R375W) and both of these changes result in the same temperature-dependence profile in their cation leak (shoulder type with a peak at 10°C, (Figure [1D](#F1){ref-type="fig"}). A different mutation in ABCB6 is associated with the Cardiff pedigree (R723Q), whose cation leak shows a U-shaped temperature-dependence (Figure [1B](#F1){ref-type="fig"}). Hence, the cation leak in this type of FP only becomes apparent at temperatures lower than 20°C and further increases as the temperature decreases. Although the vast majority of FP mutations seem to be very rare, the SNP database suggests that the R723Q mutation has a frequency of 1 in 500 (Bawazir et al., [@B15]). The temperature-dependent activation of these leaks during the processing and storage of RBC concentrates for use in transfusion medicine should be a concern when selecting units for transfusion of high-risk patients such as neonates (Bawazir et al., [@B15]).

Three further mutations in ABCB6 have been reported in FP families. The Arg276Trp mutation has been found alone, and in trans to the Arg723Gln mutation, in two separate families (Andolfo et al., [@B8]), and the Val454Ala mutation has been found in a Bolivian family (Andolfo et al., [@B8]). Andolfo et al. present data to show that the Arg276Trp and Val454Ala mutations increase cation permeability of HEK293 cells over-expressing these mutant ABCB6 proteins, and show evidence of a slight increase in cation permeability in FP RBCs with the Arg276Trp mutation. Interestingly the family with the Arg276Trp mutation is the Irish family from Omagh that were initially classified as DHSt with FP (Table [1](#T1){ref-type="table"}; Stewart et al., [@B111]). The temperature profile was assigned as parallel (Figure [1E](#F1){ref-type="fig"}) but may fit better in the U-shaped classification (Figure [1B](#F1){ref-type="fig"}) as the temperature profile is similar to the FP-Cardiff profile although milder (note the different Y-axis scales on Figures [1B,D](#F1){ref-type="fig"}). It would not be expected that the Arg276Trp mutation would cause a large difference in cation permeability because it is classified as "benign" in the Single Nucleotide Polymorphism database: <https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=57467915> and this mutant has a fairly high population frequency in the European population. This would therefore be expected to have caused more problems with blood storage and transfusion than have been reported. The high population frequency of this mutation underlines the fact that FP is an under-diagnosed condition (Andolfo et al., [@B6],[@B7]).

Unresolved---HST woking
-----------------------

An unusual case of hereditary stomatocytosis has been reported in which there is a significant cation leak (5 times greater than normal, but with a normal temperature dependence pattern), yet there was minimal hemolysis observed and nearly normal osmotic fragility (Jarvis et al., [@B72]). The affected offspring of the propositus experienced an even milder phenotype. The authors speculated that the discrepancy between the grossly abnormal cation content and mild phenotype was because the sodium and potassium abnormalities were relatively balanced (Jarvis et al., [@B72]). The genetic basis for this variant is unknown and has not been mapped.

HST mutations in affecting the regulation of cation channels {#s8}
============================================================

PIEZO1 mutations
----------------

Dehydrated hereditary stomatocytosis (DHSt; also known as hereditary xerocytosis) is a condition, similar to FP that falls at the milder end of the cation leaky spectrum. DHSt RBCs exhibit an elevation in their passive cation leak at 37°C of around twice normal, and the temperature-dependence profiles of the leak (shown in Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}) have been reported as shallow slope (Figure [1C](#F1){ref-type="fig"}), parallel (Figure [1D](#F1){ref-type="fig"}), sigmoidal (Figure [1E](#F1){ref-type="fig"}) or flat to 30°C (Figure [1G](#F1){ref-type="fig"}). This can mean that the relative increase in cation permeability of DHSt cells is augmented at lower temperatures. Indeed, all four panels show an increased cation leak relative to the control at 20°C, most markedly in the parallel and flat to 30°C profiles, however only the parallel profile shows an increased cation leak at 4°C (Figure [1](#F1){ref-type="fig"}). It should be noted that most of the profiles shown in the shallow slope graph (Figure [1C](#F1){ref-type="fig"}) are the HSt Blackburn type caused by mutations in *SLC4A1*. With hind sight, it may be that the Edinburgh profile would fit better as a mild form of the parallel profile. This tendency for DHSt RBCs to have a very minor difference in cation permeability at 37°C but maintain an increased cation leak, relative to the control, at lower temperature explains why DHSt is so often associated with pseudohyperkalemia.

The nature of the cation leak in DHSt cells is imbalanced, in that there is a greater loss of potassium from the cells than the increase in sodium, which leads to dehydration of the RBC. The dehydrated cells are accordingly more osmotically resistant than controls, and also have an unexplained increased susceptibility to oxidants (Harm et al., [@B65]). Individuals with DHSt exhibit mild hemolytic anemia with increased reticulocytes and macrocytosis. Unlike in other hemolytic anemias, splenectomy is not recommended for patients with DHSt because it often results in thrombo-embolic events (Stewart et al., [@B111]).

After a long search for the molecular basis of DHSt a breakthrough was finally made, where mutations in the gene encoding PIEZO1, *FAM38A*, were discovered to be associated with the disorder (Zarychanski et al., [@B121]). The PIEZO1 protein forms part of a mechanosensitive transduction channel (Coste et al., [@B35]). PIEZO1 is a very large protein, predicted to cross the membrane 36--39 times and has been identified in RBC membranes using mass spectrometry and Western blotting methods (Zarychanski et al., [@B121]; Andolfo et al., [@B4]). It has been shown to induce cationic fluxes in response to mechanical stimulation in eukaryotic cells (Coste et al., [@B35]). Expression of wild type PIEZO1 in *X. levis* oocytes resulted in mechano-stimulated currents that were not observed in uninjected oocytes. These currents were also observed in PIEZO1-expressing oocytes subjected to hypotonic and hypertonic induced swelling and shrinkage, respectively (Andolfo et al., [@B4]). Comparison of the conductances of normal and DHSt (with mutation R2456H) RBCs using cell-attached recording showed that DHSt cells exhibited a conductance that could be inhibited with tarantula toxin, GsMTx-4, supporting the hypothesis that the cation leak is mediated by PIEZO1 (Andolfo et al., [@B4]). Expression of DHSt mutant PIEZO1 proteins in HEK293T cells revealed that all six of the tested mutations result in slower inactivation of the current (Albuisson et al., [@B1]). This gain-of-function pattern would be consistent with the observed dehydrated phenotype. Conversely knockdown of PIEZO1 in zebrafish or mouse results in swollen cells (Faucherre et al., [@B43]; Cahalan et al., [@B27]).

It therefore seems probable that different mutations in the two genes known to be associated with DHSt and FP can result in highly similar phenotypes. Equally, different mutations within the same gene can result in distinct phenotypes, as has also been seen in the other stomatocytosis variants. For example, some mutations affect the transport ability of the proteins while others do not, and the two *RHAG* mutations resulting in OHSt give rise to subtly different phenotypes (Table [1](#T1){ref-type="table"}). Although the ability of PIEZO1 or ABCB6 to transport their usual substrates has not been fully characterized in DHSt and FP RBCs, it is possible that inhibited transport may affect the resulting phenotype. This is particularly interesting in the case of PIEZO1, which has been shown to act as a stretch sensor in RBCs and to play a key role in RBC volume regulation (Zarychanski et al., [@B121]). Recent studies have shown that the DHSt mutations in PIEZO1 cause a partial gain-of-function phenotype (Albuisson et al., [@B1]; Andolfo et al., [@B4]). Generation of mechanically activated currents inactivate more slowly than wild type. However in addition to delayed channel inactivation, additional alterations have been found in mutant PIEZO1 channel kinetics, differences in response to osmotic stress, and altered membrane protein trafficking, predicting variant alleles that worsen or ameliorate erythrocyte hydration (Glogowska et al., [@B54]).

DHSt is occasionally associated with perinatal ascites (buildup of fluid in the baby\'s abdominal cavity) and/or nuchal translucency (buildup of fluid at the back of the baby\'s head observed during ultrasound scans) (Entezami et al., [@B42]; Ami et al., [@B3]). Andolfo et al. ([@B4]) investigated the tissue expression pattern of PIEZO1 and found that it was expressed in the peritoneal lymphatic vessels in fetal, but not adult, samples. This expression pattern is consistent with the observed phenotype of edema that spontaneously self-corrects just after birth (Andolfo et al., [@B4]). It is of interest that the mutations detected in DHSt with associated ascites have also been found in DHSt cases where ascites has not been reported. It is possible that this is an under-reported condition, and that some cases have not been detected or diagnosed, especially when the edema resolves prenatally (personal communication from Prof Jean Delaunay, 2013). The severity of the edema appears to vary between cases, even those with the same mutation in PIEZO1, and may suggest the presence of a modifying gene. In recent years, numerous PIEZO1 mutations have been reported associated with DHSt alone, DHSt with pseudohyperkalemia and /or with edema (see Table [1](#T1){ref-type="table"}).

Gardos channel mutations
------------------------

After the breakthrough discovery that mutations in PIEZO1 cause various forms of DHSt, several groups have recently published studies showing that mutations in the Gardos channel (heterozygous substitutions Val282Glu, Val282Met, Arg352His), encoded by the gene *KCNN4*, are associated with DHSt (Andolfo et al., [@B9]; Glogowska et al., [@B53]; Rapetti-Mauss et al., [@B96]). Functional analysis of the R352H mutant suggested that it was 10-fold more sensitive to activation by calcium and also remained in the open conformation longer than the wild type protein (Rapetti-Mauss et al., [@B96]).

These findings have led to the hypothesis that DHSt result from a malfunction in the regulation of the joint activity of the Gardos channel and PIEZO1. In wild-type RBC, passage through constricted splenic slits or small capillary beds is associated with transient calcium-mediated adaptions (Danielczok et al., [@B37]). It is proposed that this transient increase in intracellular calcium is mediated by the opening of the PIEZO1 channel, which opens in response to the shear stress of the constricted space. The rise in intracellular calcium then causes the Gardos channel to open with the loss of potassium, followed by chloride ions and water, thus dehydrating the cell. This would make the Gardos channel the essential determinant of RBC dehydration in HSt (Rapetti-Mauss et al., [@B97]), regardless of whether the mutation was in PIEZO1 causing a prolonged influx of calcium or in KCNN4 making the Gardos channel more sensitive to intracellular calcium.

Despite the discovery of the genes responsible for DHSt, it is still not clear why many individuals with DHSt have been reported to exhibit a propensity to iron overload (Syfuss et al., [@B117]). It has been suggested that dyserythropoiesis in these conditions may play a role but this is yet to be confirmed (Andolfo et al., [@B9]).

Origin of the cation leak in the hereditary stomatocytoses {#s9}
==========================================================

Once it was discovered that band 3 mutations result in a cation leak, the mechanism of the leak was debated. In the initial report it was suggested that cation movements were conducted directly though the mutant band 3, and further investigation of the band 3 CHC mutations supported this proposal (Bruce et al., [@B25]; Guizouarn et al., [@B60]). However, Bogdanova et al. reported increased cation transport via the K(Na)/H exchanger and the K,Cl cotransporter in CHC RBCs leading to the proposal of an alternative mechanism whereby the mutant band 3 activates other endogenous transporters in the membrane, causing the cation imbalance (Bogdanova et al., [@B20]; Stewart et al., [@B109]). It is interesting to note that cation-leaky band 3 point mutations are mainly clustered around the same region in the protein, between transmembrane span 8 and span 12, the region of the protein intimately involved in anion transport (Arakawa et al., [@B10]) (Figure [2](#F2){ref-type="fig"}). The exception to this is the Leu687Pro mutation which is in TM 8 at the interface of the core and gate domains. This mutation may obstruct the movement between these two domains and thereby affect anion exchange and the correct packing of the protein (Figure [2](#F2){ref-type="fig"}).

Modeling RhAG based on the structure of *Nitrosomonas europea* Rh50 protein predicted that the OHSt mutations resulted in widening of the central channel and its conversion into a cation pore (Bruce et al., [@B23]). The leak in OHSt increases with temperature in a linear pattern, consistent with the hypothesis of the conversion of RhAG into a constitutively open cation channel. The more complex temperature-dependence of the other HSt leaks might suggest a less clear cut mechanism of cation leak. In the cryohydrocytosis types, the leak is even enhanced at lower temperatures. The GLUT1 mutations responsible for sdCHC have been modeled, with Gly286Asp predicted to result in a more rigid protein structure and Ile435DEL predicted to result in longer range conformational changes that are hard to model accurately (Flatt et al., [@B46]). This distinct temperature dependence and lack of structural evidence for the formation of a pore suggest that the cation leak may not be conducted directly through the transport channel of GLUT1. Instead, the leak may be mediated via altered protein-protein or protein-lipid interactions. Both band 3 and GLUT1 have been shown to participate in larger protein complexes (Bruce et al., [@B22]; Khan et al., [@B73]), so it is conceivable that small alterations in their structures, and resultant macro-structures, could provide gaps through which the leak could occur. Alternatively, small alterations in protein-lipid interactions could provide a pathway for cations across the membrane. It is becoming more evident that the surfaces of proteins contain specific lipid binding sites that are important for the proper expression and function of the protein in the membrane (reviewed by Palsdottir and Hunte, [@B92]). Perturbation of these interactions could be thought of as a weakening of the lipid "seal" around the protein. At lower temperatures membranes become more rigid, which could exacerbate the poor fit of lipids around mutant proteins and their multi-protein complexes and provide an explanation for how and why the leaks worsen at low temperatures.

Given that mutations in 4 different large multi-spanning membrane proteins have now been associated with these cation leaky conditions it seems unlikely that a distinct cation transporter pathway is being activated and causing the cation imbalance. Rather, it appears to be the general rule that mutation in any large multi-spanning membrane protein can provoke a cation leak if it is expressed at the RBC plasma membrane.

More recently the discovery and characterization of mutations in PIEZO1 and the Gardos channel in DHSt have been made. This has revealed a second, alternative mechanism behind HSt, in which an over-active mutant cation channel is responsible for the observed increase in membrane permeability to cations.

Other incidences of stomatocytic morphology {#s10}
===========================================

The presence of stomatocytes in the blood is not exclusive to the cation-leaky disorders. Phytosterolemia is a recessively-inherited condition in which cholesterols and plant-derived sterols are absorbed from the gut in a deregulated manner. The excess of phytosterols in the blood can result in stomatocytosis and large platelets (Rees et al., [@B98]). It is thought that the phytosterols are able to partition into the membranes of circulating RBCs and selectively expand the inner leaflet of the bilayer, inducing an inward curve in the membrane that leads to the adoption of stomatocytic morphology. Indeed, the quantity of stomatocytic cells can vary widely, and they are often not overtly predominant in blood smears from hereditary stomatocytosis pedigrees. Blood smears commonly appear normal in familial pseudohyperkalemia and in DHSt abnormal cells are principally target cells, not stomatocytes.

Summary {#s11}
=======

At present the evidence strongly suggests that there are two distinct mechanisms underlying the pathological increase in cation permeability of the RBC membrane in hereditary stomatocytosis. Modifications in a variety of multi-spanning membrane proteins including band 3, RhAG, GLUT1 and ABCB6 can result in formation of a cation pore or otherwise disrupt the membrane to allow unregulated cation movement across the membrane. Alternatively, modifications to existing cation channels such as PIEZO1 and the Gardos channel can alter their activation and deactivation kinetics, leading to increased opening and allowing greater cation fluxes than in wild type. The degree and character of the "leakiness" in these conditions can vary greatly, illustrated by the diverse phenotypes found in HSt.
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